Specialist
Former VP at GlaxoSmithKline
Agenda
- Key trends impacting the flu vaccine market, including COVID-19, entrance of mRNA vaccine technology and others, highlighting existing manufacturing hurdles
- Potential of mRNA technology for flu vaccines in light of developments from Sanofi's (PAR: SAN) Translate Bio acquisition and Pfizer's (NYSE: PFE) efforts
- Key market developments, including Novavax’s (NASDAQ: NVAX) NanoFlu
- Potential for bundling and/or combining flu vaccine with the COVID-19 vaccine – population sentiment considerations and potential commoditisation risks
- Outlook for Q4 2021 and beyond
Questions
1.
Could you start by breaking down efficacy across the various flu vaccines, building upon our previous Interview [see Influenza Vaccines – Next-generation mRNA Vaccines & Market Update – Part 1 – 7 October 2021]? My understanding is that it’s about 40-60% efficacy.
2.
What are the main hurdles to the manufacturing or delivery of the different technologies, such as cell based or egg-based?
3.
Pfizer says it is seeking improve on flu vaccine efficacy with its mRNA approach. What minimum level of efficacy would you want in order to justify the use of next-generation flu vaccines over traditional?
4.
Companies are now seeking to bundle or combine the flu vaccine with the COVID-19 vaccine. Novavax has a phase 3 underway for its NanoFlu vaccine, and some experts are speculating this could be bundled with its COVID-19 candidate to produce a seasonal flu plus COVID-19 vaccine. What’s your general take on this discussion, and how do you expect it to evolve?
5.
Do you have any further commentary around the testing that’s underway on COVID-19 and flu vaccine combinations? The first clinical trial has shown the combination is safe and appears to provide protection against COVID-19 and the flu. Moreover, we then received news yesterday that Sanofi says its flu vaccine can be co-administered with Moderna’s COVID-19 shot. What are your thoughts on those developments?
6.
Could combining the flu and COVID-19 vaccines help alleviate some of the hesitancy around the COVID-19 vaccine, or would you expect the opposite whereby more people are more hesitant around a two-in-one?
7.
What are your thoughts on Novavax’s NanoFlu vaccine in development? What is most or least impressive to you from the phase 3 results which were presented in The Lancet Infectious Diseases journal?
8.
Is there anything we’ve yet to discuss about mRNA-based influenza or COVID-19 vaccines that you think is important for investors to understand?
Gain access to Premium Content
Submit your details to access up to 5 Forum Transcripts or to request a complimentary one week trial.
The information, material and content contained in this transcript (“Content”) is for information purposes only and does not constitute advice of any type or a trade recommendation and should not form the basis of any investment decision.This transcript has been edited by Third Bridge for ease of reading. Third Bridge Group Limited and its affiliates (together “Third Bridge”) make no representation and accept no liability for the Contentor for any errors, omissions or inaccuracies in respect of it. The views of the specialist expressed in the Content are those of the specialist and they are not endorsed by, nor do they represent the opinion of, Third Bridge. Third Bridge reserves all copyright, intellectual and other property rights in the Content. Any modification, reformatting, copying, displaying, distributing, transmitting, publishing, licensing, creating derivative works from, transferring or selling any Content is strictly prohibited